A population based strategy to prevent insulin-dependent diabetes using nicotinamide

Journal of Pediatric Endocrinology and Metabolism

Volumn 9, Issue 5, 1996, Pages 501-509

  Elliott, Robert B ^a   Pilcher, Colleen C ^a   Fergusson, David M ^b   Stewart, Alistair W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Islet cell antibodies; Nicotinamide; Prevention; School children; Type 1 diabetes

Indexed keywords

ENDURAMIDE; NICOTINAMIDE; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; HYPOTHESIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MORBIDITY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0029856169     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1996.9.5.501     Document Type: Article

References (18)

1. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 1990; 31: 749-753.
2. Reddy S, Bibby NJ, Elliott RB. Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels. Diab Res 1990; 15: 95-102.
3. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362-365.
4. Elliott RB, Mandrup-Poulsen T. The use of nicotinamide to prevent type 1 diabetes. In: Palmer JP, ed. Diabetes Prediction, Prevention and Genetic Counselling in IDDM. Chichester: J. Wiley & Sons Ltd, 1996; 283-292.
5. Schatz D, Krischer J, Home G, et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest 1994; 93: 2403-2407.
6. Elliott RB, Pilcher CC. A universal model of antibody prediction (MAP) of type 1 diabetes in children. J Autoimmun 1994; 7: 881-889.
7. New Zealand Census figures for 1986 and 1991.
8. Murray DM, Hannan PJ, Zucker DM. Analysis issues in school-based health promotion studies. H Educ Q 1989; 16: 315-320.
9. Murray DM, Hannan PJ. Planning for the appropriate analysis in school-based drug-use prevention studies. J Consult Clin Psychol 1990; 58: 458-468.
10. Zucker DM, Lakatos E, Webber LS, et al. Statistical design of the child and adolescent trial for cardiovascular health (CATCH): implications of cluster randomization. Controlled Clin Trials 1995; 16- 96-118.
11. Pilcher CC, Elliott RB. A sensitive and reproducible method for the assay of human islet cell antibodies. J Immunol Meth 1990; 129: 111-117.
12. Bingley PJ, Colman P, Eisenbarth GS, et al. Standardisation of IVGTT to predict IDDM. Diabetes Care 1992; 151: 1313-1316.
13. Klenk DC, Hermanson GT, Krohn RI. et al. Determination of glycosylated haemoglobin by affinity chromatography: comparison with colorimetric and ion-exchange methods, and effects of common interferences. Clin Chem 1982; 28: 2088-2094.
14. Elliott RB, Pilcher CC, Edgar BW. The effect of nicotinamide on newly diagnosed diabetic children. Diab Res Clin Prac 1988; 5 (Suppl 1): S176.
15. Vardi P, Dib SA, Tuttleman M, et al. Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus. Diabetes 1987; 36: 1286-1291.
16. 1-methylnicotinamide in urine. Am J Clin Nutr 1977; 30: 2108-2116.
17. Diabetes Epidemiology Research International Group. Secular trends in incidence of childhood IDDM in 10 countries. Diabetes 1990; 39: 858-864.
18. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995; 57: 6-15.